254 related articles for article (PubMed ID: 7948298)
1. Thrombolytic therapy in acute myocardial infarction--selected recent developments.
Bode C; Nordt TK; Runge MS
Ann Hematol; 1994 Oct; 69(4):S35-40. PubMed ID: 7948298
[TBL] [Abstract][Full Text] [Related]
2. Intravenous thrombolytic therapy with a combination of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator in acute myocardial infarction.
Bode C; Schuler G; Nordt T; Schönermark S; Baumann H; Richardt G; Dietz R; Gurewich V; Kübler W
Circulation; 1990 Mar; 81(3):907-13. PubMed ID: 2106403
[TBL] [Abstract][Full Text] [Related]
3. Newer thrombolytic drugs for acute myocardial infarction.
Reddy DS
Indian J Exp Biol; 1998 Jan; 36(1):1-15. PubMed ID: 9536645
[TBL] [Abstract][Full Text] [Related]
4. Thrombolysis with recombinant unglycosylated single-chain urokinase-type plasminogen activator (saruplase) in acute myocardial infarction: influence of heparin on early patency rate (LIMITS study). Liquemin in Myocardial Infarction During Thrombolysis With Saruplase.
Tebbe U; Windeler J; Boesl I; Hoffmann H; Wojcik J; Ashmawy M; Rüdiger Schwarz E; von Loewis P; Rosemeyer P; Hopkins G
J Am Coll Cardiol; 1995 Aug; 26(2):365-73. PubMed ID: 7608436
[TBL] [Abstract][Full Text] [Related]
5. Sequential combination thrombolytic therapy for acute myocardial infarction: results of the Pro-Urokinase and t-PA Enhancement of Thrombolysis (PATENT) Trial.
Zarich SW; Kowalchuk GJ; Weaver WD; Loscalzo J; Sassower M; Manzo K; Byrnes C; Muller JE; Gurewich V
J Am Coll Cardiol; 1995 Aug; 26(2):374-9. PubMed ID: 7608437
[TBL] [Abstract][Full Text] [Related]
6. Influence of time to treatment on early infarct-related artery patency after different thrombolytic regimens. ALKK-Study Group.
Zeymer U; Tebbe U; Essen Rv; Haarmann W; Neuhaus KL
Am Heart J; 1999 Jan; 137(1):34-8. PubMed ID: 9878934
[TBL] [Abstract][Full Text] [Related]
7. [Thrombolytic therapy in acute myocardial infarct].
Bode C; Baumann H; von Hodenberg E; Kübler W
Med Klin (Munich); 1992 Feb; 87(2):64-9. PubMed ID: 1542285
[No Abstract] [Full Text] [Related]
8. New plasminogen activators: a clinical review.
Ross AM
Clin Cardiol; 1999 Mar; 22(3):165-71. PubMed ID: 10084057
[TBL] [Abstract][Full Text] [Related]
9. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. The RAPID II Investigators.
Bode C; Smalling RW; Berg G; Burnett C; Lorch G; Kalbfleisch JM; Chernoff R; Christie LG; Feldman RL; Seals AA; Weaver WD
Circulation; 1996 Sep; 94(5):891-8. PubMed ID: 8790022
[TBL] [Abstract][Full Text] [Related]
10. Effects of lipoprotein (a) on success rate of thrombolytic therapy in acute myocardial infarction.
von Hodenberg E; Kreuzer J; Hautmann M; Nordt T; Kübler W; Bode C
Am J Cardiol; 1991 Jun; 67(16):1349-53. PubMed ID: 1828324
[TBL] [Abstract][Full Text] [Related]
11. New developments in thrombolytic therapy.
Collen D; Gold HK
Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
[TBL] [Abstract][Full Text] [Related]
12. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. RAPID Investigators.
Smalling RW; Bode C; Kalbfleisch J; Sen S; Limbourg P; Forycki F; Habib G; Feldman R; Hohnloser S; Seals A
Circulation; 1995 Jun; 91(11):2725-32. PubMed ID: 7758177
[TBL] [Abstract][Full Text] [Related]
13. [Development of new thrombolytic substances].
Zeymer U; Neuhaus KL
Herz; 1994 Dec; 19(6):314-25. PubMed ID: 7843688
[TBL] [Abstract][Full Text] [Related]
14. Patency trials with reteplase (r-PA): what do they tell us?
Bode C; Nordt TK; Peter K; Smalling RW; Runge MS; Kübler W
Am J Cardiol; 1996 Dec; 78(12A):16-9. PubMed ID: 8990406
[TBL] [Abstract][Full Text] [Related]
15. Increased thrombin levels during thrombolytic therapy in acute myocardial infarction. Relevance for the success of therapy.
Gulba DC; Barthels M; Westhoff-Bleck M; Jost S; Rafflenbeul W; Daniel WG; Hecker H; Lichtlen PR
Circulation; 1991 Mar; 83(3):937-44. PubMed ID: 1900225
[TBL] [Abstract][Full Text] [Related]
16. Coronary arterial thrombolysis with low-dose synergistic combinations of recombinant tissue-type plasminogen activator (rt-PA) and recombinant single-chain urokinase-type plasminogen activator (rscu-PA) for acute myocardial infarction.
Collen D; Van de Werf F
Am J Cardiol; 1987 Sep; 60(7):431-4. PubMed ID: 3115077
[TBL] [Abstract][Full Text] [Related]
17. The role of thrombolytic drugs in the management of myocardial infarction. Comparative clinical trials.
Weaver WD
Eur Heart J; 1996 Dec; 17 Suppl F():9-15. PubMed ID: 8960443
[TBL] [Abstract][Full Text] [Related]
18. [Plasminogen activators as thrombolytic agents in myocardial infarction].
Chamone DA; Massumoto C; Fujimura AY; Pileggi F; Bellotti G
Rev Hosp Clin Fac Med Sao Paulo; 1989; 44(6):288-94. PubMed ID: 2518605
[TBL] [Abstract][Full Text] [Related]
19. Current state of thrombolytic therapy.
Vorchheimer DA
Curr Cardiol Rep; 1999 Sep; 1(3):212-20. PubMed ID: 10980844
[TBL] [Abstract][Full Text] [Related]
20. Coronary reperfusion studies with pro-urokinase in acute myocardial infarction: evidence for synergism of low dose urokinase.
Kasper W; Hohnloser SH; Engler H; Meinertz T; Wilkens J; Roth E; Lang K; Limbourg P; Just H
J Am Coll Cardiol; 1990 Sep; 16(3):733-8. PubMed ID: 2117622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
